Homepage Top Section2

With a differentiated mechanism of action, momelotinib has inhibitory ability along three important signalling pathways, Janus kinase (JAK) 1, and JAK2 and activin A receptor type I (ACVR1).

The financing round was co-led by ORI Capital, Longitude Capital and Decheng Capital. It has also seen participation from RA Capital Management, Acorn Bioventures, Malin Corporation, Ally Bridge

Nearly 1,600 people in England alone are expected to benefit from the immunotherapy drug. Previously, the drug was available for a small group of people with advanced TNBC

The new, oral formulation of CD/LD extended-release capsules, IPX203 features immediate-release granules and extended-release beads. Findings from the pivotal Phase III RISE-PD clinical trial showed that the extended-release

Under the deal terms, the company will provide funding for clinical development of its next-generation antibody-drug conjugate (ADC), NAV-001. The experimental ADC targets and kills tumour cells which

The double-blind, multicentre, placebo-controlled, randomised, dose-finding Phase II OCEAN(a)-DOSE study was designed for evaluating olpasiran’s tolerability, safety, as well as the optimal dose in atherosclerotic cardiovascular disease (ASCVD)

The financial details of the agreement are not disclosed by the companies. Under the deal, CSL will acquire exclusive and global license to TS23, an enhanced first-in-class anti-α2-antiplasmin

The collaboration will use Charles River’s contract development and manufacturing (CDMO) services to manufacture plasmid DNA and viral vectors for late-stage clinical trials that target degenerative ocular diseases,

The new combined formulation will be delivered using a breath-actuated nebuliser. Currently, AeroRx is said to be engaged in the development of the first nebulised LABA/LAMA combination solution